Overview
First book on that topic
Input and perspectives by international leaders?
Preclinical and clinical data available on the subject have been integrated
A dedicated chapter on toxicity profile of mTOR inhibitors
Future directions for the development of mTOR inhibitors
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (13 chapters)
-
Front Matter
-
Back Matter
Keywords
About this book
This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs.
Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation.
Editors and Affiliations
About the editors
Monica Mita and Alain Mita are Associate Professors of Medicine and Co-Directors of the Experimental Therapeutics Program at the Samuel Oschin Comprehensive Cancer institute, Cedars-Sinai Medical Center in Los Angeles, CA. Eric Rowinsky is Chief Medical Officer, Head of Research and Development, and Executive Vice President at Stemline Therapeutics, Inc. He is also an Adjunct Professor of Medicine at New York University School of Medicine and a cancer drug development consultant at Oncodrugs.
Bibliographic Information
Book Title: mTOR Inhibition for Cancer Therapy: Past, Present and Future
Editors: Monica Mita, Alain Mita, Eric K. Rowinsky
DOI: https://doi.org/10.1007/978-2-8178-0492-7
Publisher: Springer Paris
eBook Packages: Medicine, Medicine (R0)
Copyright Information: Springer-Verlag France 2016
Hardcover ISBN: 978-2-8178-0491-0Published: 01 December 2015
Softcover ISBN: 978-2-8178-0557-3Published: 23 August 2016
eBook ISBN: 978-2-8178-0492-7Published: 18 November 2015
Edition Number: 1
Number of Pages: VI, 300
Topics: Oncology, Hematology, Molecular Medicine
Industry Sectors: Biotechnology, Health & Hospitals, Pharma